Startup · $6m raised · Healthcare
Adelaide, SA
Every investor coverage indicates participated in a round FerronovaPrecision cancer treatment technology raised.
| Investor | Rounds | Invested |
|---|---|---|
| Artesian VC | Series A | - |
| Renew Pharmaceuticals | Series A | - |
| South Australian Venture Capital Fund | Series A | - |
| Uniseed/UniSuper | Series A | - |
Investors whose own portfolio pages list FerronovaPrecision cancer treatment technology, even though we haven't found any coverage of the round yet.
| Investor | Listed on |
|---|---|
| Stoic Venture Capital | its portfolio page ↗ |
| Stoic Venture Capital | its portfolio page ↗ |
Companies FerronovaPrecision cancer treatment technology acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr John Parker | Chair (former) | ferronova.com.au |
| Stewart Bartlett | CEO (former) | movefm.com.au, ferronova.com.au (17 Dec 2025), ferronova.com.au (22 Jan 2023) |
Stories naming FerronovaPrecision cancer treatment technology. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Adelaide medtech Ferronova has banked another $6 million from returning backers to advance its surgical tracer for cancer, lifting Series A funding to $17.5 million; backer parent UltraGreen.ai floated in Singapore this month.
Also movefm.com.au
Adelaide biotech Ferronova announced an A$11 million package: an A$8 million round led by Ireland's Renew Pharmaceuticals plus an A$3 million government CRC-P grant, with existing shareholders Uniseed and Artesian also participating.